Ken Griffin Bristol Myers Squibb CO Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Citadel Advisors LLC holds 3,922,500 shares of BMY stock, worth $219 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
3,922,500
Previous 6,918,500
43.3%
Holding current value
$219 Million
Previous $358 Million
38.03%
% of portfolio
0.04%
Previous 0.07%
Shares
30 transactions
Others Institutions Holding BMY
# of Institutions
2,751Shares Held
1.57BCall Options Held
28MPut Options Held
28.7M-
Vanguard Group Inc Valley Forge, PA190MShares$10.6 Billion0.19% of portfolio
-
Black Rock Inc. New York, NY159MShares$8.86 Billion0.15% of portfolio
-
Jpmorgan Chase & CO New York, NY96MShares$5.36 Billion0.44% of portfolio
-
State Street Corp Boston, MA95.1MShares$5.31 Billion0.22% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA60.3MShares$3.37 Billion0.65% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $119B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...